Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma

Grande, Mirtha; Carlström, Kjell; Lundh-Rozell, Barbro; Stege, Reinhard; Pousette, Åke

doi:10.1080/00365590500193304

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detection of PAP in serum was the primary prostate cancer screening test used until the 1990s when it was supplanted by the more sensitive and specific assay for prostate-specific antigen (PSA). There is renewed interest in PAP as a prognostic tissue marker for T4 tumors [22], as a serum marker in clinical staging of prostate cancer [23], and for predicting recurrence after radical prostatectomy [24]. PAP is expressed in > 95% of the primary prostate adenocarcinomas as determined by IHC [11,12,15].…”

Section: Introductionmentioning

confidence: 99%

Prostatic acid phosphatase expression in human tissues

Graddis

McMahan

Tamman³

et al. 2010

Clinical Cancer Research

View full text Add to dashboard Cite

Prostate cancer is the most common cancer and the second leading cause of cancer deaths among males in most Western countries. Autologous cellular immunotherapy for the treatment of cancer seeks to induce tumorspecific immunity in the patient and is consequently dependent on a suitable target antigen and effective presentation of that antigen to the patient's immune system. Prostatic acid phosphatase (PAP) has been tested as a target antigen due to its high and apparently specific expression in the prostate. We used a variety of approaches to analyze PAP expression, including immunohistochemistry, in situ hybridization, and quantitative polymerase chain reaction. We complemented these laboratory-based techniques with an in silico analysis of reported PAP expression in human cDNA libraries. Our studies confirmed that, while PAP expression is not restricted to prostate tissues, its expression in other human tissues is approximately 1-2 orders of magnitude less than that observed in the prostate. The relative specificity of PAP expression in the prostate supports its use as a target of autologous cellular immunotherapy. The approach described here, involving the use of multiple correlates of tissue-specific expression, is warranted as a prerequisite in selecting any suitable target for immunotherapy.

show abstract